openPR Logo
Press release

Global Depression Treatment Market Share 2021: Global Trends, Key Players, Industry Analysis Report to 2027

05-07-2021 01:23 PM CET | Health & Medicine

Press release from: Orion Market Research

The global depression treatment Market is anticipated to grow at a CAGR of 4.1% during the forecast period (2020-2027). The increasing number of FDA approvals for antidepressants along with the expansion in pipeline products by key market players are certain factors driving the growth of the depression treatment industry.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/depression-treatment-market

In February 2021, Zydus Cadila has received US FDA approval for Nortriptyline Hydrochloride Capsules USP. The capsules come up in the strength of 10 mg, 25 mg, 50 mg, and 75 mg. Nortriptyline Hydrochloride Capsules USP is majorly used for the treatment of depression.

Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/depression-treatment-market

Moreover, in July 2020, VistaGen Therapeutics, a US-based biopharmaceutical company had received US FDA approval for PH94B under Phase 3 development to treat acute anxiety and mental illness in adult patients with a social anxiety disorder (SAD). PH94B is an investigational rapid-onset neurosteroid nasal spray majorly used for the treatment of social anxiety disorder.
Furthermore, in March 2019, Johnson & Johnson’s ketamine-derived nasal spray Spravato for treatment-resistant depression has been approved by the FDA. The Spravato CIII Nasal Spray is used for the treatment of depressive disorder in adults with a high risk of major depressive disorder (MDD). Thus, these approvals by the FDA for antidepressant drugs produced by major key players, the depression treatment market is expected to witness significant growth during the forecast period.

Market Segmentation
By Drug Type
• Selective Serotonin Reuptake Inhibitors
• Tricyclic Antidepressants
• Serotonin-Norepinephrine Reuptake Inhibitors
• Monoamine Oxidase Inhibitors
• Others

Regional Analysis
North America
• United States
• Canada

Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific
• China
• Japan
• India
• Rest of the Asia-Pacific

Rest of the World

Company Profiles
• Alkermes Plc
• Allergen Plc
• AstraZeneca plc
• Bausch Health Companies, Inc.
• Eli Lilly and Co.
• F. Hoffmann-La Roche AG
• Garmin Ltd.
• GlaxoSmithKline plc
• H. Lundbeck A/S
• Johnson & Johnson Services, Inc.
• Lief Therapeutics
• Lupin Ltd.
• MagVenture, Inc.
• Mylan N.V.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer, Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/depression-treatment-market

Media Contact:
Company name: Orion Market Research
Contact person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Depression Treatment Market Share 2021: Global Trends, Key Players, Industry Analysis Report to 2027 here

News-ID: 2281605 • Views:

More Releases from Orion Market Research

Hematopoietic Stem Cell Transplantation Market Analysis and Forecast 2024-2031
Hematopoietic Stem Cell Transplantation Market Analysis and Forecast 2024-2031
The global hematopoietic stem cell transplantation market is anticipated to grow at a considerable CAGR during the forecast. The Major driver in the hematopoietic stem cell transplantation market is the growing network of hematopoietic stem cell transplantation organizations that have reached across the globe and have been seen by an NGO called the Worldwide Network for Blood and Marrow Transplantation Group officially affiliated with the World Health Organization. The growing
Guidewires Market Size, Trends, Latest Insights, Analysis and Forecast 2024-2031
Guidewires Market Size, Trends, Latest Insights, Analysis and Forecast 2024-2031
The global guidewires market is anticipated to grow at a considerable CAGR of 4.9% during the forecast. The increasing prevalence of minimally invasive surgical practices in major regions will drive the market growth. Minimally invasive medical practices have a numerous advantages over open procedures, including shorter hospital stays, speedier patient recovery, increased operational safety and effectiveness, and lower costs. Healthcare practitioners are continually turning for alternative treatments that give patients
Gene Therapy Products Market Will Exhibit an Impressive Expansion by 2024-2031
Gene Therapy Products Market Will Exhibit an Impressive Expansion by 2024-2031
The global gene therapy products market is anticipated to grow at a significant CAGR during the forecast period. Gene therapy is an advanced medical treatment involving the transfer of a normal/ healthy gene to replace a defective gene in a cell. The market growth is majorly attributed owing to the growing incidences of various chronic and genetic disorders in human beings that can be cured through gene therapy. Gene therapy
Eisenmenger Syndrome Treatment Market Will Exhibit an Impressive Expansion by 2024-2031
Eisenmenger Syndrome Treatment Market Will Exhibit an Impressive Expansion by 20 …
The global eisenmenger syndrome treatment market is anticipated to grow at a CAGR during the forecast period. The triad of systemic-to-pulmonary congenital cardiovascular communication, pulmonary arterial disease, and cyanosis is called Eisenmenger syndrome. The major factor that drives the market is consistent regulatory approval to the key players operating in the global market for the treatment of Eisenmenger syndrome by providing drugs, and therapy is expected to drive the market

All 5 Releases


More Releases for FDA

FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility
Peyronie’s Disease Market - Only FDA approved product
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30). Announcing New Design Control Training Courses Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation. GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet
11-09-2016 | Science & Education
GRCTS
FDA online training
Description: Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding